MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010
Debt
Debt-to-Equity RatioN/A
Current Ratio6.02
Quick Ratio5.69
Price-To-Earnings
Trailing P/E Ratio-10.32
Forward P/E Ratio-9.01
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.50 million
Price / Sales69.25
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book17.78
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-22,140,000.00
Net Margins-783.30%
Return on Equity-210.90%
Return on Assets-33.92%
Miscellaneous
Employees76
Outstanding Shares27,050,000
Market Cap$175.81 million
Mediwound (NASDAQ:MDWD) Frequently Asked Questions
What is Mediwound's stock symbol?
Mediwound trades on the NASDAQ under the ticker symbol "MDWD."
How were Mediwound's earnings last quarter?
Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.05. The biopharmaceutical company earned $1.03 million during the quarter, compared to the consensus estimate of $0.96 million. Mediwound had a negative return on equity of 210.90% and a negative net margin of 783.30%. View Mediwound's Earnings History.
When is Mediwound's next earnings date?
What price target have analysts set for MDWD?
5 equities research analysts have issued 12-month price objectives for Mediwound's stock. Their forecasts range from $9.00 to $14.00. On average, they anticipate Mediwound's stock price to reach $10.60 in the next year. This suggests a possible upside of 65.6% from the stock's current price. View Analyst Price Targets for Mediwound.
What is the consensus analysts' recommendation for Mediwound?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.
Who are some of Mediwound's key competitors?
Some companies that are related to Mediwound include Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), Conversion Labs (CVLB), ImmuDyne (IMMD), FitLife Brands (FTLF), True Drinks (TRUU), Tauriga Sciences (TAUG), Nutra Pharma (NPHC) and Entia Biosciences (ERGO).
Who are Mediwound's key executives?
Mediwound's management team includes the folowing people:
- Mr. Gal Cohen, Pres & CEO (Age 45)
- Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 72)
- Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 46)
- Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 52)
- Dr. Ety Klinger, Chief R&D Officer (Age 56)
Has Mediwound been receiving favorable news coverage?
News articles about MDWD stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Mediwound earned a coverage optimism score of 0.18 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Mediwound.
Who are Mediwound's major shareholders?
Mediwound's stock is owned by a number of of institutional and retail investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (7.76%), Renaissance Technologies LLC (0.48%) and Nexthera Capital LP (0.16%).
Which institutional investors are buying Mediwound stock?
MDWD stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Migdal Insurance & Financial Holdings Ltd. and Renaissance Technologies LLC.
How do I buy shares of Mediwound?
Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mediwound's stock price today?
One share of MDWD stock can currently be purchased for approximately $6.40.
How big of a company is Mediwound?
Mediwound has a market capitalization of $175.81 million and generates $2.50 million in revenue each year. The biopharmaceutical company earns $-22,140,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Mediwound employs 76 workers across the globe.
How can I contact Mediwound?
Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]
MarketBeat Community Rating for Mediwound (NASDAQ MDWD)
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
